Literature DB >> 21827378

Oral subchronic immunotoxicity study of ethyl tertiary butyl ether in the rat.

Marcy I Banton1, Vanessa L Peachee, Kimber L White, Eric L Padgett.   

Abstract

The potential for immunotoxicological effects of ethyl tertiary butyl ether (ETBE, CAS RN 637-92-3) was studied in young adult female Crl:CD(SD) rats following subchronic oral exposures. Rats were exposed by gavage once daily for 28 consecutive days to 0, 250, 500, or 1000 mg ETBE/kg body weight (BW)/day; a concurrent positive control group received four intraperitoneal injections of at 50 mg cyclophosphamide monohydrate (CPS)/kg/day on study Days 24-27. Immunotoxicity was evaluated using a splenic antibody-forming cell (AFC) assay to assess T-cell-dependent antibody responses in rats sensitized with sheep red blood cells (SRBC). All rats survived to the scheduled necropsy. There were no effects on clinical observations, body weights, feed or water consumption, or macroscopic pathology findings in the ETBE-treated rats. No ETBE-related effects were observed on absolute or relative (to final body weight) spleen or thymus weights, spleen cellularity, or on the specific (AFC/10(6) spleen cells) or total activity (AFC/spleen) of splenic IgM AFC to the T-cell-dependent antigen SRBC. CPS produced expected effects consistent with its known immunosuppressive properties and validated the appropriateness of the AFC assay. Based on the results of this study, ETBE did not suppress the humoral component of the immune system in female rats. The no-observed-effect level for immunotoxicity was the highest dosage tested at 1000 mg/kg/day.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827378     DOI: 10.3109/1547691X.2011.598480

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  1 in total

Review 1.  Emerging Antioxidant Paradigm of Mesenchymal Stem Cell-Derived Exosome Therapy.

Authors:  Chen Xia; Zhanqiu Dai; Yongming Jin; Pengfei Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-29       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.